RELATED PARTY TRANSACTIONS	12 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 17. RELATED PARTY TRANSACTIONS On June 30, 2021, and 2020, the Company had $7.3 million and $7.0 million, respectively, at fair value invested in USGIF funds the Company advised. These amounts were included in the Consolidated Balance Sheets as “investments in equity securities at fair value.” The Company recorded $15,000 and $97,000 in income from dividends and capital gain distributions from USGIF investments in fiscal years 2021 and 2020, respectively. There were no net realized gains or losses on its investments in the Funds in fiscal years 2021 or 2020. In addition, the Company had $158,000 at June 30, 2020, invested in a fund advised by Galileo, a related party until March 2020, accounted for under the equity method of accounting. The Company recorded loss from equity method investments of $142,000 in fiscal year 2020. See further discussion of these investments in Note 4. The Company earned advisory and administrative services fees, as applicable, from the various funds for which it acts as investment adviser, as disclosed in Note 5. Receivables include amounts due from the funds for those fees and out-of-pocket expenses, net of amounts payable to the funds for expense reimbursements. As of June 30, 2021, and 2020, the Company had $2.4 million and $869,000, respectively, of receivables from mutual funds included in the Consolidated Balance Sheets within “receivables.” The Company has had various investments in HIVE that were valued at approximately $25.1 million and $2.4 million and as of June 30, 2021, and 2020, respectively. As discussed in Note 4, in January 2021, the Company purchased convertible securities in HIVE, and an unrealized gain was recognized in other comprehensive income (loss) for the convertible debentures, which will be realized in investment income (loss) ratably using the effective interest method until maturity, conversion, or other disposition. During the fiscal year ended June 30, 2021, $1.4 million in principal payments were received, and $1.2 million was included in investment income (loss) as realized gains on principal payment proceeds. On July 1, 2018, the Company reclassified $3.2 million of unrealized gains related to its investment in HIVE from Accumulated Other Comprehensive Income (Loss) into Retained Earnings. Therefore, when a HIVE investment was sold during the fiscal year ended June 30, 2021, the amount included in realized gains on sales of fair valued securities was the proceeds of $20.6 million, less the cost of $2.4 million and the ASU 2016-01 reclassified unrealized gains of $3.2 million, or $15.0 million. The Company recorded $368,000 in interest income from HIVE investments during the fiscal year ended June 30, 2021. There was no interest income or net realized gains or losses on its investments in HIVE during the fiscal year ended June 30, 2020. The Company earned other income from HIVE for consulting fees in the amount of $40,000 during the fiscal year ended June 30, 2021. As of June 30, 2021, the Company had $40,000 of receivables from HIVE included in the Consolidated Balance Sheets within “receivables.” There was no other income earned during the fiscal year ended June 30, 2020, and no receivables as of June 30, 2020. Frank Holmes, a director and Chief Executive Officer of the Company, is the non-executive chairman of HIVE, for which he received director fees from HIVE during fiscal years 2021 and 2020. Mr. Holmes held shares and options of HIVE at June 30, 2021, and 2020. Effective August 31, 2018, upon the retirement of HIVE’s CEO and until a new CEO is hired, Mr. Holmes became Interim Executive Chairman of HIVE. As discussed in Note 4, the Company holds an investment in Thunderbird that was valued at approximately $2.7 million and $1.2 million as of June 30, 2021, and 2020, respectively. Realized gains on sales totaled $936,000 during the fiscal year ended June 30, 2021. Frank Holmes served on the board of this company as a director, for which he received fees, from June 2014 to March 2021. As discussed in Note 4, the Company had an investment in GoldSpot that was valued at approximately $806,000 as of June 30, 2020. During the year ended June 30, 2021, the Company sold its investment in GoldSpot and recorded realized gains on sales of fair valued securities of $600,000. Frank Holmes served on the board of this company as director from February 2019 to June 2020 and as independent chairman from February 2019 to May 2020 and held common stock and options at June 30, 2020.

RELATED PARTY TRANSACTIONS

12 Months Ended

Jun. 30, 2021

NOTE 17. RELATED PARTY TRANSACTIONS

On June 30, 2021, and 2020, the Company had $7.3 million and $7.0 million, respectively, at fair value invested in USGIF funds the Company advised. These amounts were included in the Consolidated Balance Sheets as “investments in equity securities at fair value.” The Company recorded $15,000 and $97,000 in income from dividends and capital gain distributions from USGIF investments in fiscal years 2021 and 2020, respectively. There were no net realized gains or losses on its investments in the Funds in fiscal years 2021 or 2020.

In addition, the Company had $158,000 at June 30, 2020, invested in a fund advised by Galileo, a related party until March 2020, accounted for under the equity method of accounting. The Company recorded loss from equity method investments of $142,000 in fiscal year 2020. See further discussion of these investments in Note 4.

The Company earned advisory and administrative services fees, as applicable, from the various funds for which it acts as investment adviser, as disclosed in Note 5. Receivables include amounts due from the funds for those fees and out-of-pocket expenses, net of amounts payable to the funds for expense reimbursements. As of June 30, 2021, and 2020, the Company had $2.4 million and $869,000, respectively, of receivables from mutual funds included in the Consolidated Balance Sheets within “receivables.”

The Company has had various investments in HIVE that were valued at approximately $25.1 million and $2.4 million and as of June 30, 2021, and 2020, respectively. As discussed in Note 4, in January 2021, the Company purchased convertible securities in HIVE, and an unrealized gain was recognized in other comprehensive income (loss) for the convertible debentures, which will be realized in investment income (loss) ratably using the effective interest method until maturity, conversion, or other disposition. During the fiscal year ended June 30, 2021, $1.4 million in principal payments were received, and $1.2 million was included in investment income (loss) as realized gains on principal payment proceeds. On July 1, 2018, the Company reclassified $3.2 million of unrealized gains related to its investment in HIVE from Accumulated Other Comprehensive Income (Loss) into Retained Earnings. Therefore, when a HIVE investment was sold during the fiscal year ended June 30, 2021, the amount included in realized gains on sales of fair valued securities was the proceeds of $20.6 million, less the cost of $2.4 million and the ASU 2016-01 reclassified unrealized gains of $3.2 million, or $15.0 million. The Company recorded $368,000 in interest income from HIVE investments during the fiscal year ended June 30, 2021. There was no interest income or net realized gains or losses on its investments in HIVE during the fiscal year ended June 30, 2020. The Company earned other income from HIVE for consulting fees in the amount of $40,000 during the fiscal year ended June 30, 2021. As of June 30, 2021, the Company had $40,000 of receivables from HIVE included in the Consolidated Balance Sheets within “receivables.” There was no other income earned during the fiscal year ended June 30, 2020, and no receivables as of June 30, 2020. Frank Holmes, a director and Chief Executive Officer of the Company, is the non-executive chairman of HIVE, for which he received director fees from HIVE during fiscal years 2021 and 2020. Mr. Holmes held shares and options of HIVE at June 30, 2021, and 2020. Effective August 31, 2018, upon the retirement of HIVE’s CEO and until a new CEO is hired, Mr. Holmes became Interim Executive Chairman of HIVE.

As discussed in Note 4, the Company holds an investment in Thunderbird that was valued at approximately $2.7 million and $1.2 million as of June 30, 2021, and 2020, respectively. Realized gains on sales totaled $936,000 during the fiscal year ended June 30, 2021. Frank Holmes served on the board of this company as a director, for which he received fees, from June 2014 to March 2021.

As discussed in Note 4, the Company had an investment in GoldSpot that was valued at approximately $806,000 as of June 30, 2020. During the year ended June 30, 2021, the Company sold its investment in GoldSpot and recorded realized gains on sales of fair valued securities of $600,000. Frank Holmes served on the board of this company as director from February 2019 to June 2020 and as independent chairman from February 2019 to May 2020 and held common stock and options at June 30, 2020.